证券代码：002688 证券简称：金河生物 公告编号：2025-013 金河生物科技股份有限公司 关于股票交易异常波动的公告 本公司及董事会全体人员保证公告内容真实、准确和完整，并对公告中的虚 假记载、误导性陈述或者重大遗漏承担责任。 一、股票交易异常波动的情况介绍 金河生物科技股份有限公司（以下简称"公司"）股票（股票简称：金河生 物，股票代码：002688）交易价格于2025年4月7日1个交易日收盘价格涨幅偏离 值达到20.73%，根据深圳证券交易所的相关规定，属于股票交易的异常波动情形。 二、公司关注并核实的情况 针对公司股票交易异常波动的情况，公司董事会就相关事项进行了自查，并 向控股股东、实际控制人及其一致行动人进行了核实，现就有关情况说明如下： 1、公司前期所披露的信息，不存在需要更正、补充之处。 2、公司未发现近期公共媒体报道了可能或已经对公司股票交易价格产生较 大影响的未公开重大信息。 4、公司、控股股东和实际控制人不存在关于公司的应披露而未披露的重大 事项，或处于筹划阶段的重大事项。在股票异常波动期间，公司控股股东、实际 控制人不存在买卖公司股票的行为。 三、是否存在应披露而未披露信息的说明 ...

Group 1 - The article highlights the significant impact of tariffs on the global market, leading to widespread declines in A-shares, with 5,211 stocks falling and 1,448 hitting the daily limit down [1] - Amidst the market downturn, only a few concept stocks related to export countermeasures and domestic substitution showed resilience [1] Group 2 - Jinhe Biological has achieved a limit-up increase, marking its fourth limit-up in seven days, with a stock price of 6.53 yuan per share and a total market capitalization of 5.038 billion yuan [2] - The trading volume for the limit-up was 131 million yuan, with the highest order amounting to 3.114 billion yuan [2] Group 3 - Other stocks related to Jinhe Biological's product, such as Meino Biological and Weilan Biological, also experienced gains, with Meino achieving two consecutive limit-ups and Weilan reaching a limit-up at one point [3] Group 4 - In response to the high tariffs imposed by the U.S. government, Jinhe Biological announced plans to increase the sales price of its premixed products in the U.S. market to ensure product quality and service, aiming for greater profit margins [4] - Jinhe Biological is a major global supplier of the antibiotic product, with the U.S. being a significant market that relies heavily on imports, as it has no large-scale domestic manufacturers [5] Group 5 - Jinhe Biological holds a strong market position with an annual production capacity of 55,000 tons and a global market share of approximately 50%, allowing it to leverage pricing power to enhance profits [5] - The company is expected to benefit from the tariff increase, which could lead to high revenue growth [5] Group 6 - After three years of decline, Jinhe Biological's performance has improved over the past two years, with net profits showing a positive trend in 2023 [6] - In the first three quarters of the previous year, the company reported revenue of 1.657 billion yuan, a year-on-year increase of 5.57%, and a net profit of 114 million yuan, up 10.38% [7] Group 7 - The company is projected to release its annual report for 2024 and the first quarter of 2025 on April 26 [7] - Future performance is expected to improve due to increased penetration of chemical products and the gradual release of vaccine products, with projected EPS for 2025 and 2026 being 0.24 yuan and 0.30 yuan, respectively [7]

Group 1 - The stock of Jinhe Biological has experienced a significant increase, with 4 limit-up days within 7 trading days, resulting in a cumulative increase of 36.90% and a turnover rate of 48.04% [1] - As of 9:27, the stock's trading volume reached 4.9443 million shares, with a transaction amount of 32.286 million yuan, and a turnover rate of 0.66% [1] - The latest total market capitalization of A-shares is 5.039 billion yuan, while the circulating market capitalization is 4.865 billion yuan [1] Group 2 - According to the latest data from the Longhu list, the stock was listed once due to a cumulative deviation of 20% in the increase over three consecutive trading days, with institutional net selling of 16.0801 million yuan and a total net buying of 71.4341 million yuan from brokerage seats [1] - The company's Q3 report for 2024 shows total operating revenue of 1.657 billion yuan for the first three quarters, representing a year-on-year increase of 5.57%, and a net profit of 114 million yuan, up 10.38% year-on-year [1] Group 3 - The stock's daily performance over the past week includes notable fluctuations, with a peak increase of 10.00% on April 3, 2025, and a significant net inflow of 109.6897 million yuan on the same day [1] - The trading data indicates a mix of gains and losses, with the stock experiencing a decline of 5.60% on March 31, 2025, and a net outflow of 3.10369 million yuan [1]

Group 1 - The company's stock (stock code: 002688) experienced an abnormal trading fluctuation, with a cumulative price increase of 26.48% over three consecutive trading days from April 1 to April 3, 2025 [2] - The company conducted a self-examination and confirmed that there were no corrections or supplements needed for previously disclosed information [3] - The company did not find any recent media reports that could have significantly impacted the stock price [4] Group 2 - The company's operational situation and external business environment have not undergone any significant changes recently [5] - The company and its major shareholders have not engaged in any undisclosed significant matters related to the company during the abnormal trading period [5] - The board confirmed that there are no undisclosed matters that should be disclosed according to the Shenzhen Stock Exchange regulations [6] Group 3 - The company is in the process of preparing its 2024 annual report and 2025 Q1 report, which will be disclosed on April 26, 2025 [7] - The company has not provided any undisclosed performance information to third parties outside of its auditing firm [7] - The designated information disclosure media for the company includes several financial newspapers and websites [7]

证券代码：002688 证券简称：金河生物 公告编号：2025-012 金河生物科技股份有限公司 关于股票交易异常波动的公告 本公司及董事会全体人员保证公告内容真实、准确和完整，并对公告中的虚 假记载、误导性陈述或者重大遗漏承担责任。 公司董事会确认，截至本公告披露日，公司目前没有任何根据《深圳证券交 易所股票上市规则》等有关规定应予以披露而未披露的事项或与该事项有关的筹 划、商谈、意向、协议等；董事会也未获悉公司有根据《深圳证券交易所股票上 市规则》等有关规定应予以披露而未披露的、对公司股票及其衍生品种交易价格 一、股票交易异常波动的情况介绍 金河生物科技股份有限公司（以下简称"公司"）股票（股票简称：金河生 物，股票代码：002688）交易价格于2025年4月1日、4月2日、4月3日连续三个交 易日收盘价格涨幅偏离值累计26.48%，根据深圳证券交易所的相关规定，属于股 票交易的异常波动情形。 二、公司关注并核实的情况 针对公司股票交易异常波动的情况，公司董事会就相关事项进行了自查，并 向控股股东、实际控制人及其一致行动人进行了核实，现就有关情况说明如下： 1、公司前期所披露的信息，不存在需要更正、补充之 ...

Core Viewpoint - The company, Jinhe Biological, announced a price adjustment plan for its end products in response to the recent U.S. tariffs on certain raw pharmaceutical products from China, aiming to maintain product quality and service while maximizing profitability in the U.S. market [1][2] Group 1: Company Strategy - Jinhe Biological will conduct thorough market research to timely increase the end sales prices of its products in the U.S. to offset the cost impact from the tariff hikes [1] - The company emphasizes strict quality control in production to gain customer trust and expand market share, ultimately enhancing economic benefits [1][2] Group 2: Market Position and Products - As a leading supplier of chlortetracycline premix, Jinhe Biological's services cover three main areas: animal protection, environmental protection, and agricultural product processing [2] - The company offers over 90 products, including chlortetracycline series animal protection products, corn starch, and various vaccines, with an annual comprehensive production capacity of 60,000 tons for its "Muxing" brand chlortetracycline premix [2] Group 3: Market Impact - Following the announcement of the price adjustment plan, Jinhe Biological's stock price opened with a 10% increase, reaching 5.94 yuan per share, with a total market capitalization of 4.584 billion yuan [2]

证券代码：002688 证券简称：金河生物 公告编号：2025-011 金河生物科技股份有限公司 关于控股股东部分股份解除质押的公告 本公司及董事会全体人员保证公告内容真实、准确和完整，并对公告中的虚 假记载、误导性陈述或者重大遗漏承担责任。 金河生物科技股份有限公司（以下简称"公司"）于近日收到控股股东内蒙 古金河控股有限公司（以下简称"金河控股"）的通知，获悉金河控股所持有本 公司的部分股份解除质押。具体事项如下： 一、股东股份解除质押基本情况 | 股东名称 | 是否为控股股东 | 本次解除 | 占其所 | 占公司 | 质押开始 | 质押解除日 | | 质权人 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 或第一大股东及 | 质押股份 | 持股份 | 总股本 | 日期 | 期 | | | | | 其一致行动人 | 数量 | 比例 | 比例 | | | | | | 金河控股 | 是 | 20,036,000 | 8.29% | 2.60% | 2022 年 07 | 2025 | 年 3 月 | 华西证券股 | | | | | | ...

Investment Rating - The report gives a "Buy" rating for the company, Jinhe Biological (stock code: 002688.SZ) [2][44]. Core Views - Jinhe Biological is a leading enterprise in the veterinary antibiotic sector, focusing on a dual-driven strategy of chemical drugs and vaccines. The company has expanded its business boundaries from veterinary raw materials to animal vaccines and environmental technology, forming a new business pattern with organic interaction among various segments [4][6][11]. - The company achieved revenue of 2.174 billion yuan in 2023, with a year-on-year growth of 2.42%, and 1.065 billion yuan in the first half of 2024, growing by 3.22% year-on-year [4][7]. - The veterinary chemical drug business remains the largest revenue contributor, while the vaccine business is expected to grow significantly as product penetration increases [44]. Summary by Sections Company Overview - Jinhe Biological was established in 1988 and has become a global leader in animal health. The company went public in 2012 and has since expanded into animal vaccines and environmental technology, creating a comprehensive animal health ecosystem [6][8]. Financial Performance - In 2023, the company reported a revenue of 2.174 billion yuan, with a projected revenue of 2.289 billion yuan in 2024, representing a growth rate of 5.30% [5][45]. - The net profit attributable to the parent company is expected to grow from 864.6 million yuan in 2023 to 1.8691 billion yuan in 2025, reflecting a growth rate of 45.47% [5][44]. Business Segments - The veterinary chemical drug segment generated 1.016 billion yuan in revenue in 2023, with a year-on-year increase of 3.27%, maintaining stable growth [11][24]. - The veterinary biological products segment achieved revenue of 335 million yuan in 2023, with a year-on-year growth of 1.48% [35]. Growth Drivers - The company is enhancing its production capacity, with a new project expected to add 60,000 tons of chemical drug capacity by October 2024, increasing total production capacity to 115,000 tons [24][29]. - Jinhe Biological is actively expanding its pet business, establishing a subsidiary in Shanghai in 2024, with several products already on the market and more in development [19][24]. Research and Development - The company has invested in R&D, with 74 million yuan spent in 2023, focusing on innovation and product quality improvement [19][24]. - Jinhe Biological has a rich pipeline of over 20 vaccine products in development, including vaccines for pigs and pets, which are expected to contribute to future revenue growth [40][42].

证券代码：002688 证券简称：金河生物 公告编号：2025-009 一、股东股份质押的基本情况 二、股东股份累计质押的情况 截至公告披露日，控股股东金河控股及其一致行动人路牡丹、王志军、路漫 | 漫、王晓英所持质押股份情况如下： | | --- | 金河生物科技股份有限公司 关于控股股东部分股份质押的公告 本公司及董事会全体人员保证公告内容真实、准确和完整，并对公告中的虚 假记载、误导性陈述或者重大遗漏承担责任。 金河生物科技股份有限公司（以下简称"公司"）于近日收到控股股东内蒙 古金河控股有限公司（以下简称"金河控股"）的通知，获悉金河控股所持有本 公司的部分股份质押。具体事项如下： | 股东 | 是否为控股 股东或第一 | 本次质押数 | 占其所 持股份 | 占公司 总股本 | 是否 为限 | 是否为 补充质 | 质押开始 | 质押到期 | 质权人 | 质押 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 名称 | 大股东及其 | 量（股） | | | | | 日期 | 日 | | 用途 | | | 一致行 ...

金河生物科技股份有限公司（以下简称"公司"）子公司金河佑本生物制品 有限公司（以下简称"金河佑本"）于近日获得由国家知识产权局颁发的发明专 利证书，具体情况如下： 1、证书号：第 7754581 号 2、发明名称：一种犬瘟热病毒和犬细小病毒的二联亚单位疫苗及其制备方 法和应用 证券代码：002688 证券简称：金河生物 公告编号：2025-010 金河生物科技股份有限公司 关于子公司取得发明专利证书的公告 本公司及董事会全体人员保证公告内容真实、准确和完整，并对公告中的虚 假记载、误导性陈述或者重大遗漏承担责任。 特此公告。 金河生物科技股份有限公司 董 事 会 3、专利权人：金河佑本生物制品有限公司 4、地址：010000 内蒙古自治区呼和浩特市和林格尔县盛乐经济园区盛乐五 街北(北奇公司东) 5、发明人：李雪峰；康斌；郭海军；武玉梅；董鹏；张金龙；赵炳武；王 家福 6、专利号：ZL 2022 1 1403119.4 7、专利申请日：2022 年 11 月 10 日 8、授权公告号:CN 116059338 B 9、授权公告日：2025 年 02 月 25 日 本发明创新地实现了一次表达纯化过程即可同时生产 ...